Pharmaceutical Technology
JUNE 24, 2022
invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 The post invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m appeared first on Pharmaceutical Technology.
Pharmaceutical Technology
MARCH 1, 2023
Sunshine Biopharma has signed an exclusive global licence deal with the University of Arizona for PLpro-based Covid-19 treatment. Since February last year, Sunshine Biopharma has been working along with the University of Arizona on this project. Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 11, 2022
As the space regroups, join the likes of Compugen , iTeos Therapeutics , Genentech , Mereo BioPharma , Gilead Sciences , Nectin Therapeutics , Shattuck Lab s, Graphite Bio , GlaxoSmithKline and many more to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs.
pharmaphorum
DECEMBER 20, 2022
That’s impressive, as it has proved exceedingly difficult for pharmacological therapies to show an impact on fibrosis in prior studies. Similarly, a one-stage or greater improvement in liver fibrosis was seen in 24% and 26% of the resmetirom groups, respectively, versus 14% of patients taking placebo.
Clarivate
FEBRUARY 28, 2023
Frontiers in Pharmacology; 13:1089033; DOI: 10.3389/fphar.2022.1089033 .” Ophthalmology; V.127; 5; 5/2020; p679; DOI: 10.1016/j.ophtha.2019.11.014 2019.11.014 [8] Giannuzzi V et al. Editorial: The Use of Real World Data for Regulatory Purposes in the Rare Diseases Setting.”
European Pharmaceutical Review
JANUARY 27, 2025
His career has spanned various roles including brand protection utilising novel technologies at De La Rue, to numerous QC, scientist and project management roles in Eli Lilly, Patheon (now Thermo Fisher), Catalent and Porton Biopharma. Neil obtained a degree in medicinal and pharmaceutical chemistry from Loughborough University.
MedCity News
JUNE 16, 2023
The earliest higher-profile digital therapeutic leaders focused on mental and behavioral health with some earning Food and Drug Administration approval for managing conditions such as attention-deficit and hyperactivity disorder, substance-use disorder, and insomnia using a prescription-level app alone or in conjunction with pharmacologic therapy.
Expert insights. Personalized for you.
64 
Let's personalize your content